Alamar Biosciences, Inc. ALMR
At closeNov 3, 2026, 4:00 PM EST
After hours · Nov 3, 4:00 PM ET
- YTD
- +37.36%
- 1 year
- +37.36%
- Market cap
- 2.10B
- Revenue (ttm)
- 100.42M
- Profit margin
- -49.45%
- EPS (ttm)
- -1.20
- Shares out
- 69.39M
- Forward P/E
- -66.89
- YTD return
- +37.36%
- 1-year return
- +37.36%
- Volume
- 673.92K
- Avg volume
- 557.51K
- Open
- 29.18
- Previous close
- 28.94
- Day's range
- 29.18 – 30.29
- 52-week range
- 18.85 – 39.61
- Price target
- 35.40 (+17.1%)
- Earnings date
- Mar 3, 2027
2Y +8.14 (+37.00%)
Key statistics
- Enterprise value
- 1.81B
- PEG ratio
- 0.00
- Price / sales
- 20.88
- Price / book
- 6.70
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 82.10%
- Free cash flow
- 0
- Total cash
- 250.05M
- Total debt
- 51.41M
- Return on equity
- 0.00%
- Short % of float
- 6.25%
- 50-day average
- 30.54
- 200-day average
- 26.94
Analyst view
- Target (low)
- 31.00
- Target (mean)
- 35.40
- Target (high)
- 45.00
- Strong buy1
- Buy3
- Hold1
- Sell0
- Strong sell0
Next earnings
Mar 3, 2027
Expected Mar 3, 2027. Consensus EPS estimate -0.18688.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 3, 2027 | Dec 30, 2026 | -0.20993 | — | — | — |
| Nov 3, 2026 | Sep 30, 2026 | -0.2015 | -0.19 | +0.01 | +5.71% |
| Aug 10, 2026 | Jun 30, 2026 | -0.30787 | -0.22 | +0.09 | +28.54% |
| May 8, 2026 | Mar 31, 2026 | -1.71 | -1.74 | -0.03 | -1.75% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 11, 2026 | Stifel | main | Buy | Buy |
| Aug 11, 2026 | JP Morgan | main | Overweight | Overweight |
| May 12, 2026 | Leerink Partners | init | — | Outperform |
| May 12, 2026 | TD Cowen | init | — | Buy |
| May 12, 2026 | JP Morgan | init | — | Overweight |
| May 12, 2026 | Stifel | init | — | Buy |
About Alamar Biosciences, Inc.
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomarker analysis across the continuum of discovery, translational research and ultimately, and diagnostics. The company's offering is utilized in research areas including immunology, neurology, and oncology. It serves global research and academic institutions, biopharmaceutical companies, contract research organizations, and service labs. The company operates in the United States, rest of Europe, Middle East and Africa, Germany, Asia Pacific, and internationally. It has a strategic partnership with Alzheimer's Disease Data Initiative, and Gates Ventures to advance translational research in alzheimer's disease. The company was incorporated in 2018 and is based in Fremont, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- alamarbio.com
News
Alamar Biosciences, Inc. (ALMR) Q3 2026 Earnings Call Transcript 
Alamar Biosciences Q3 Earnings Call Highlights 
Alamar (ALMR) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates 
Alamar Biosciences Q3 2026 Earnings Call Transcript 
Alamar Biosciences Raises FY2026 Sales Guidance from $116.000M-$120.000M to $121.000M-$123.000M vs $118.632M Est 
Alamar Biosciences Q3 EPS $(0.19); Sales $33.55M Up 68% From $19.91M YoY 
Alamar Biosciences Partners With GSK For Its Use Of NULISA Platform In Trial To Evaluate Protein Signatures Regarding Disease Progression, Biological Subtypes And Treatment Response Across Respiratory, Liver, Kidney, Neurological And Autoimmune Conditions 
Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance 
Alamar Biosciences Partners with GSK on Large-Scale Proteomic Study to Advance Precision Medicine 
UPDATE -- Alamar Biosciences and Nightingale Health to Lead UK Biobank 80,000-Sample Neurodegenerative Disease Study
Your note
Sign in to keep a note on ALMR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHEN SHIPING PH.D. | Chief Operating Officer | Stock Award(Grant) | Apr 19, 2026 | 760,105 |
| ILLUMINA INNOVATION FUND II GP, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 19, 2026 | 0 |
| LUO YULING PH.D. | Chief Executive Officer | Stock Award(Grant) | Apr 19, 2026 | 3,164,730 |
| MCANEAR JUSTIN J | Chief Financial Officer | Stock Award(Grant) | Apr 19, 2026 | 37,220 |
| NACLERIO NICHOLAS J. | Director | Stock Award(Grant) | Apr 19, 2026 | 6,369,300 |
| QIMING CORPORATE GP VI, LTD. | Beneficial Owner of more than 10% of a Class of Security | Sale | Oct 25, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Sands Capital Alternatives, LLC | 6.10% | 4,230,926 | 127.86M | Jun 29, 2026 |
| Samsara BioCapital, LLC | 3.57% | 2,480,310 | 74.95M | Jun 29, 2026 |
| T. Rowe Price Investment Management, Inc. | 3.17% | 2,202,597 | 66.56M | Jun 29, 2026 |
| ARK Investment Management, LLC | 1.98% | 1,373,959 | 41.52M | Jun 29, 2026 |
| Braidwell LP | 1.56% | 1,083,983 | 32.76M | Jun 29, 2026 |
| Alliancebernstein L.P. | 1.45% | 1,003,077 | 30.31M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK ETF Trust-ARK Genomic Revolution ETF | 1.42% | 984,456 | 29.75M | Sep 29, 2026 |
| ARK Venture Fund | 0.96% | 667,717 | 20.18M | Jul 30, 2026 |
| AB CAP FUND, INC.-AB Small Cap Growth Portfolio | 0.87% | 601,045 | 18.16M | Aug 30, 2026 |
| Columbia Funds Series Trust I-Columbia Small Cap Growth Fund | 0.68% | 472,554 | 14.28M | Aug 30, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 0.51% | 355,864 | 10.75M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 0.50% | 345,070 | 10.43M | Sep 29, 2026 |